# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone mar...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Actinium Pharma (AMEX:ATNM) with a Overweight rating and a...
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of ...
Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Inve...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...
Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price ta...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...